日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma

三重野生型黑色素瘤中 CDK9 抑制脆弱性的分子背景

Samantha M Guhan, Michael Shaughnessy, Anpuchchelvi Rajadurai, Michael Taylor, Raj Kumar, Zhenyu Ji, Sarem Rashid, Keith Flaherty, Hensin Tsao

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

靶向细胞外基质重塑可恢复 BRAFi 耐药黑色素瘤对 BRAF 抑制剂的敏感性

Charles Marusak, Varsha Thakur, Yuan Li, Juliano T Freitas, Patrick M Zmina, Vijay S Thakur, Mayland Chang, Ming Gao, Jiufeng Tan, Min Xiao, Yiling Lu, Gordon B Mills, Keith Flaherty, Dennie T Frederick, Benchun Miao, Ryan J Sullivan, Tabea Moll, Genevieve M Boland, Meenhard Herlyn, Gao Zhang, Barba

Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies

NOXA mRNA不稳定是靶向治疗常见的耐药机制

Joan Montero ,Cécile Gstalder ,Daniel J Kim ,Dorota Sadowicz ,Wayne Miles ,Michael Manos ,Justin R Cidado ,J Paul Secrist ,Adriana E Tron ,Keith Flaherty ,F Stephen Hodi ,Charles H Yoon ,Anthony Letai ,David E Fisher ,Rizwan Haq

Selective uveal melanoma inhibition with calcium channel blockade

通过钙通道阻滞剂选择性抑制葡萄膜黑色素瘤

Michael Shaughnessy, Grace Lamuraglia, Nikolai Klebanov, Zhenyu Ji, Anpuchchelvi Rajadurai, Raj Kumar, Keith Flaherty, Hensin Tsao

Intraoperative Infusion of Dexmedetomidine for Prevention of Postoperative Delirium and Cognitive Dysfunction in Elderly Patients Undergoing Major Elective Noncardiac Surgery: A Randomized Clinical Trial

术中输注右美托咪定预防老年择期非心脏大手术患者术后谵妄和认知功能障碍:一项随机临床试验

Deiner, Stacie; Luo, Xiaodong; Lin, Hung-Mo; Sessler, Daniel I; Saager, Leif; Sieber, Frederick E; Lee, Hochang B; Sano, Mary; Jankowski, Christopher; Bergese, Sergio D; Candiotti, Keith; Flaherty, Joseph H; Arora, Harendra; Shander, Aryeh; Rock, Peter

Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response

颗粒酶 B PET 成像作为免疫疗法反应的预测生物标志物

Benjamin M Larimer, Eric Wehrenberg-Klee, Frank Dubois, Anila Mehta, Taylor Kalomeris, Keith Flaherty, Genevieve Boland, Umar Mahmood

Distinct histone modifications denote early stress-induced drug tolerance in cancer

独特的组蛋白修饰表明癌症早期应激诱导的药物耐受性

Abdullah Al Emran, Diego M Marzese, Dinoop Ravindran Menon, Mitchell S Stark, Joachim Torrano, Heinz Hammerlindl, Gao Zhang, Patricia Brafford, Matthew P Salomon, Nellie Nelson, Sabrina Hammerlindl, Deepesh Gupta, Gordon B Mills, Yiling Lu, Richard A Sturm, Keith Flaherty, Dave S B Hoon, Brian Gabri

Elucidating distinct roles for NF1 in melanomagenesis

阐明NF1在黑色素瘤形成中的不同作用

Ophélia Maertens, Bryan Johnson, Pablo Hollstein, Dennie T Frederick, Zachary A Cooper, Ludwine Messiaen, Roderick T Bronson, Martin McMahon, Scott Granter, Keith Flaherty, Jennifer A Wargo, Richard Marais, Karen Cichowski

Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth

Vemurafenib 与 nutlin-3 协同作用,消耗 survivin,抑制黑色素瘤活力和肿瘤生长

Zhenyu Ji, Raj Kumar, Michael Taylor, Anpuchchelvi Rajadurai, Alexander Marzuka-Alcalá, Y Erin Chen, Ching-Ni Jenny Njauw, Keith Flaherty, Göran Jönsson, Hensin Tsao

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases

针对 AKT 存活通路的过度激活来克服黑色素瘤脑转移的治疗耐药性

Heike Niessner, Andrea Forschner, Bernhard Klumpp, Jürgen B Honegger, Maria Witte, Antje Bornemann, Reinhard Dummer, Annemarie Adam, Jürgen Bauer, Ghazaleh Tabatabai, Keith Flaherty, Tobias Sinnberg, Daniela Beck, Ulrike Leiter, Cornelia Mauch, Alexander Roesch, Benjamin Weide, Thomas Eigentler, Dir